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Primary ciliary dyskinesia (PCD) is a genetically heterogeneous
recessive disorder of motile cilia that leads to oto-sino-pulmonary
diseases and organ laterality defects in approximately 50%of cases.
The estimated incidence of PCD is approximately 1 per 15,000 births,
but the prevalence of PCD is difficult to determine, primarily because
of limitations in diagnostic methods that focus on testing ciliary
ultrastructure and function. Diagnostic capabilities have recently
benefitted from (1) documentation of low nasal nitric oxide produc-
tion in PCD and (2) discovery of biallelic mutations in multiple
PCD-causing genes. The use of these complementary diagnostic
approaches shows that at least 30% of patients with PCD have nor-
mal ciliary ultrastructure. More accurate identification of patients
with PCD has also allowed definition of a strong clinical phenotype,
which includes neonatal respiratory distress in.80% of cases, daily
nasal congestion and wet cough starting soon after birth, and early
development of recurrent/chronicmiddle-ear and sinus disease. Re-
cent studies, using advanced imaging and pulmonary physiologic
assessments, clearly demonstrate early onset of lung disease in
PCD, with abnormal air flowmechanics by age 6–8 years that is sim-
ilar to cystic fibrosis, and age-dependent onset of bronchiectasis.
The treatmentof PCD isnot standardized, and therearenovalidated
PCD-specific therapies. Most patients with PCD receive suboptimal
management, which should include airway clearance, regular sur-
veillance of pulmonary function and respiratory microbiology, and
use of antibiotics targeted to pathogens. The PCD Foundation is
developing a network of clinical centers, which should improve
diagnosis and management of PCD.
Keywords: primary ciliary dyskinesia; Kartagener syndrome; nasal nitric
oxide; genetics; newborn respiratory distress syndrome
Primary ciliary dyskinesia (PCD; onlineMendelian inheritance in
manno. 244400 [http://www.ncbi.nlm.nih.gov/Omim/]) is a genet-
ically heterogeneous recessive disorder of motile cilia that results
in neonatal respiratory distress, chronic oto-sino-pulmonary
disease,male infertility, and organ laterality defects in approximately
50% of cases (1–4). Initial recognition of this syndrome in 1933
was based on the triad of chronic sinusitis, bronchiectasis, and
situs inversus, known as Kartagener syndrome (5). In 1976,
Afzelius (6) reported that these patients had “immotile” cilia and
defective ciliary ultrastructure; however, subsequent studies dem-
onstrated that most patients had cilia with stiff, uncoordinated,
and/or ineffective ciliary beat. Therefore, “primary” was adopted
for the term PCD for this heterogeneous disorder, to distinguish it
from secondary or acquired ciliary defects associated with in-
fection and inflammation.
PCD has an estimated incidence of 1 per 10,000–20,000 births,
based on population surveys of situs inversus and bronchiectasis
in Norway and Japan (7, 8). The prevalence of PCD in the
United States is difficult to determine, largely due to inadequa-
cies of diagnostic methods (9). There are fewer than 1,000
patients in the United States with a well established diagnosis of
PCD, because many providers do not appreciate the cardinal
signs and symptoms, especially in infants and children. Further-
more, diagnostic tests of cilia ultrastructure and/or function are
not standardized or readily available. Therapy is not specific for
PCD, but rather extrapolated from other diseases, particularly
cystic fibrosis (CF) and idiopathic bronchiectasis.
Even though the quality of tests of ciliary ultrastructure
(9–11) and/or function (9, 12, 13) has improved in a few special-
ized centers, we now recognize that some patients cannot be
diagnosed by these tests, because as many as 30% of patients
with PCD have normal ciliary ultrastructure and/or subtle, non-
diagnostic changes in ciliary waveform (9–13). Diagnostic capa-
bilities have recently benefited from the development of a new
screening test for PCD, involving measurement of nasal nitric
oxide (nNO) (14, 15). Genetic testing is also becoming a reality,
with recent discovery of PCD-causing genetic mutations (2–4,
16, 17). Furthermore, better definition of genotype/phenotype
has led to better recognition of the early onset and severity of
clinical disease in children with PCD (4, 18–21). This progress
has benefited from an National Institutes of Health–sponsored
Rare Disease Network (http://rarediseases.info.nih.gov/) and
our rare disease consortium focused on studying genetic disor-
ders of mucociliary clearance (http://rarediseasesnetwork.epi.
usf.edu/gdmcc/), as well as expansion of U.S. PCD centers that
recently occurred on the 10th anniversary of the founding of the
PCD Foundation (http://www.pcdfoundation.org/).
This review provides an overview of the rapidly evolving state
of the art for clinical disease in PCD, including limitations in the
diagnosis and treatment of PCD and description of progress that
promises to revolutionize the identification and treatment of
patients with PCD (1–4). Some results have been previously
reported in abstract form (19).
(Received in original form February 5, 2013; accepted in final form May 24, 2013)
Supported by National Institutes of Health grants R01HL071798, 5 U54HL096458,
and 2T32HL007106-36.
Correspondence and requests for reprints should be addressed to Michael R.
Knowles, M.D., Cystic Fibrosis/Pulmonary Research and Treatment Center,
7011 Thurston-Bowles Building, CB# 7248, University of North Carolina, Chapel
Hill, NC 27599-7248. E-mail: knowles@med.unc.edu
Am J Respir Crit Care Med Vol 188, Iss. 8, pp 913–922, Oct 15, 2013
Copyright ª 2013 by the American Thoracic Society
Originally Published in Press as DOI: 10.1164/rccm.201301-0059CI on June 24, 2013
Internet address: www.atsjournals.org
 
STRUCTURE AND FUNCTION OF MOTILE
AND NONMOTILE CILIA
Overview of Different Types of Cilia
Motilecilia intherespiratorytracthaveacomplexaxonemalstruc-
ture for generation of functional ciliary motility (22, 23). Special-
ized motile cilia in the embryonic node have a rotary motion to
direct laterality of organs during embryogenesis (24). There are
also nonmotile (sensory or primary) cilia, which do not contain
components necessary for motility (25, 26). Mutations in genes
encoding proteins involved in biogenesis, structure, and/or func-
tion of motile and nonmotile cilia cause ciliopathies, which have
a broad range of phenotypes (25, 26) (see subsequent text).
Normal Motile (9 1 2) Cilia
Cilia are evolutionarily conserved organelles, as evidenced by
homologies with Chlamydomonas (2, 16). Motile cilia have
microtubules of a- and b-monomers of tubulin, and associated
accessory elements (23) (Figure 1). Outer dynein arms (ODAs)
and inner dynein arms (IDAs) are present along the length of
the peripheral microtubules (doublets), and contain enzymes
for ATP hydrolysis (22, 23). Nexin links (nexin–dynein regula-
tory complex) connect the doublets, and radial spokes extend
from the doublets to the central pair to provide structural sup-
port necessary for cilia bending (27). Mutations in genes encod-
ing the axonemal structure or functional components of motile
cilia, or necessary for the biogenesis of cilia, including cytoplas-
mic proteins, can result in PCD.
Embryonic Nodal Motile (9 1 0) Cilia
During early embryonic development (gastrulation), cells in the
ventral node contain a single motile cilium per cell. This special-
ized motile cilium has nine peripheral doublets and dynein arms,
but lacks the central pair ofmicrotubules, andhas a rotarymotion,
which facilitates development of organ laterality during embryo-
genesis (24). In the absence of normal nodal ciliary function,
organ placement is random.Mutations in genes that encode com-
ponents of the nine outer doublets result in a laterality defect
(situs inversus or situs ambiguus) in approximately 50% of
patients with PCD, but mutations in genes that encode for com-
ponents of the central apparatus (central pair, radial spokes, etc.)
do not cause laterality defects (2, 16).
Nonmotile, Primary, or Sensory (9 1 0) Cilia
Most cells of the body have a single nonmotile cilium, which con-
tains specialized proteins/receptors to sense the local environ-
ment. These cilia are involved in signaling pathways, and play
a key role in planar cell polarity (25, 26). Mutations in genes
encoding proteins necessary for biogenesis or function of nonmo-
tile cilia cause disorders involving multiple organs (e.g., Bardet-
Biedl syndrome, nephronophthisis, retinitis pigmentosa, Joubert
syndrome, and autosomal dominant polycystic kidney disease,
which sometimes has associated bronchiectasis) (25, 26, 28).
Function of Normal Motile Cilia
Mucociliary clearance is themost important innate defensemech-
anism in the lung, and cilia provide the coordinated motive force
for clearingbacteria and toxic substances from the conducting air-
ways (29). ATP hydrolysis in dynein arms generate force to in-
duce sliding of adjacent axonemal structures, and the complex
ciliary waveform in human airways (12, 13, 22, 23, 30). Approxi-
mately 200 cilia per cell beat in a coordinated fashion across each
cell and across multiple cells, and this coordinated vectorial syn-
chrony results from both planar orientation and training by cilia-
driven fluid flow (31, 32). The cilia beat in-plane, and the forward
(power) stroke is more rapid and extends a bit higher into the
mucus layer than the recovery stroke (30). The wave-like move-
ment across cells results from tightly packed cilia beating at ap-
proximately 6–12 Hz. Regulation of ciliary beating involves
signaling molecules, including cAMP, cGMP, Ca21, and NO
(22). The ability for 200 cilia on each cell to beat so rapidly reflects
the very low friction among cilia, which results from negatively
charged glycoproteins that coat the ciliary shaft (33).
CLINICAL PHENOTYPE EARLY IN LIFE
Overview
Mucociliary clearance is a primary innate defense mechanism,
and the clinical features of PCD reflect defective function of mo-
tile cilia in the conducting airways, paranasal sinuses, middle ear
(eustachian tube), and the reproductive tract, as well as special-
ized motile cilia in the ventral node during embryogenesis (29)
(Table 1). Manifestations of PCD occur at birth and within the
first several months of life (18, 19). Knowledgeable clinicians
should be able to establish the likelihood of PCD, based on the
clinical phenotype (9, 18), which has recently been rigorously
defined through systematic analysis in our rare disease consor-
tium (see subsequent section, CLINICAL PHENOTYPE) (19).
Respiratory Distress in Term Neonates
Earlymanifestations of PCDoccur in the neonatal period, as over
80% of full-term neonates with PCD have respiratory distress.
These infants have tachypnea, increased work of breathing, and
frequently require supplemental oxygen for a few hours to weeks
(18–20). These infants are often diagnosed with transient tachyp-
nea of the newborn or neonatal pneumonia. This neonatal pre-
sentation implies that normal ciliary function plays a critical role
in the clearance of fetal lung fluid, although the mechanism is
unknown. The presence of unexplained respiratory distress and
radiographic abnormalities (e.g., atelectasis and/or increased
perihilar/interstitial markings), along with supplemental oxygen
requirements in a full-term infant, should raise suspicion for
PCD, particularly in neonates with situs inversus (20, 21).
Figure 1. Normal motile cilia (9 1 2) configuration. Motile cilia are
composed of highly complex microtubules of a- and b-monomers of
tubulin, and associated accessory elements.
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Oto-Sino-Pulmonary Manifestations
Common findings in infants and children with PCD include daily
nasal congestion (rhinitis) and year-round wet cough occurring
soon after birth. Chronic otitis media that results in temporary or
sometimes permanent hearing loss and recurrent sinus infections
are classic features. Often, sinusitis is not diagnosed in young
children secondary to lack of radiographic imaging. Bronchiec-
tasis occurs in some infants and preschoolers (21). Chest com-
puted tomography (CT) scans show a variety of abnormalities,
including atelectasis, air trapping, thickened airway walls, and
mucous plugging (21, 34–36). Because respiratory manifesta-
tions overlap with other common early childhood diseases
(e.g., recurrent respiratory viral infections, gastroesophageal
reflux), the diagnosis of PCD is frequently missed, despite the
presence of cardinal clinical features, even when coupled to
situs inversus. This lack of knowledge highlights the importance
of education for many specialties, including neonatology, pul-
monology, cardiology, otolaryngology, and for primary care
providers.
PROGRESSION OF LUNG DISEASE: INFANCY
TO ADULTHOOD
Overview
Nearly 100% of infants and children with PCD have a persistent
daily wet cough. Cough clearance may partially compensate for
defective mucociliary clearance, but recurrent/chronic bacterial
infections in the lower airways inevitably occur, and there is age-
dependent development of bronchiectasis, which is universal in
adults with PCD (18, 34, 37).
Respiratory Microbiology
Pulmonary bacteriology of children is dominated by Haemophi-
lus influenza, Staphylococcus aureus, and Streptococcus pneu-
moniae; however, a surprising number of children, including
infants/preschoolers, also intermittently culture Pseudomonas
aeruginosa, which emerges as chronic airway infection in teen-
agers and young adults (18, 37). Some patients culture more
than one type of bacteria in the same sample. The respiratory
microbiology in PCD parallels that in CF, although chronic
P. aeruginosa infection occurs at an older age in PCD and
S. pneumoniae is a frequent pathogen in PCD, but not CF
(37). The prevalence of nontuberculous mycobacteria (NTM)
also parallels that seen in CF, with approximately 15% of adults
with PCD having positive NTM cultures, but a lower prevalence
in children with PCD (37)
Lung Function
Lung disease in children with PCD is not mild, in contrast to gen-
eral perceptions. Abnormal lung function can develop early in
life, as many infants and young children demonstrate abnormal
airflow mechanics (21, 38–41). The range of FEV1 is heteroge-
neous in PCD at age 6–8 years; indeed, some young patients
have severe obstructive impairment that is worse than patients
with CF at a comparable age. Cross-sectional and longitudinal
data show that spirometry worsens with increasing age (39).
However, airflow obstruction does not progress as rapidly in
late childhood and early adulthood compared with CF, which
is possibly related to preservation of cough clearance. In one
longitudinal study, lung function remained stable in PCD chil-
dren who received aggressive treatment (40). Patients with PCD
have spirometric evidence of decreased FEF25–75 values and
ventilation inhomogeneity, as measured through multiple
breath washout (42).
Lung Imaging
Imaging studies show that lung disease in PCD begins in infancy
or early childhood, as revealed on high-resolution chest CT.
These findings manifest as subsegmental atelectasis, peribron-
chial thickening, mucus plugging, and/or evidence of air trapping
and ground-glass opacity. Bronchiectasis can occur during in-
fancy, and inevitably develops as disease progresses (21). Ap-
proximately 50–75% of older pediatric patients and nearly all
adults with PCD have bronchiectasis with predilection for mid-
dle lobe, lingula, and basal segments (34–36). Similar to CF,
chest CT scanning is more accurate to assess early PCD lung
disease compared with spirometric indices (38). Chest high field
3T magnetic resonance imaging appears to be as effective as
high-resolution chest CT in assessing the extent and severity
of lung abnormalities in PCD, making this radiation-free imag-
ing technique an intriguing option for longitudinal assessment
and research studies (43).
NONPULMONARY MANIFESTATIONS
Laterality Defects: Situs Inversus Totalis or Situs Ambiguus
Situs abnormalities are present in approximately 60% of pedi-
atric patients, as compared with approximately 50% of adults,
TABLE 1. AGE-RELATED PREVALENCE OF PRIMARY CILIARY DYSKINESIA CLINICAL FEATURES
BY SITE OF DYSFUNCTIONAL CILIA
Location of Dysfunctional Cilia





Embryonic node Laterality defect (situs inversus totalis
or heterotaxy)
Neonatal to school age* —–
Eustachian tube Chronic/recurrent otitis media Infancy Infancy
Transient hearing loss/speech delays Infancy to preschool ——
Nose/paranasal sinuses Year-round, daily nasal congestion Infancy Infancy
Chronic pansinusitis† Preschool School age
Trachea/bronchi Unexplained neonatal respiratory distress Neonatal Perinatal
Recurrent lower respiratory infections Infancy Preschool
Bronchiectasis School age Adult
Sperm Infertility Adult —–
* For all children with primary ciliary dyskinesia (PCD), prevalence of laterality defect is greater than 50%; however, for all
individuals (children and adults) with PCD, prevalence of laterality is likely close to, but not greater than, 50% (37). This
discrepancy likely reflects earlier pursuit of PCD diagnostic testing in children with situs inversus totalis.
y Pansinusitis is seen in almost all patients with PCD who have sinus imaging studies, but these studies are not done very often
in pre-school age patients.
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which suggests that abnormal situs serves as a marker to aid ear-
lier recognition. Situs abnormalities reflect defective function of
the 91 0 motile cilium at the node during embryogenesis (24). A
subset of patients with situs ambiguus have heterotaxia syn-
dromes, including polysplenia (left isomerism) and asplenia
(right isomerism). At least 6% of patients with PCD have situs
ambiguous, and these patients have a 200-fold increased likeli-
hood of having structural congenital heart disease comparedwith
the general population with heterotaxy (44, 45). This observation
links congenital heart disease with cilia defects. There are in-
creased postoperative respiratory complications in patients with
heterotaxy andcongenital heart disease,which suggests that some
of these patientsmay have PCD (46). Indeed, studies inmicewith
mutations (Dnai1) in motile cilia suggest that cilia are required
for normal heart development (looping) (47).Moreover, patients
with heterotaxy and congenital heart disease have a high preva-
lence of respiratory ciliary dysfunction, which highlights the crit-
ical role of cilia function in normal cardiac development (48, 49).
Fertility Status
Infertility is almost universal in men with PCD, secondary to dys-
motility of spermatozoa.However, somemenwithPCDare azoo-
spermic, and a few have normal spermmotility and have fathered
children (50). Females have impaired ciliary function in the fal-
lopian tubes, and may have reduced fecundity or a history of
ectopic pregnancies related to delayed ovum transit through the
fallopian tube (51).
Pectus Excavatum and Scoliosis
Pectus excavatum occurs in approximately 10% of patients with
PCD, as compared with 0.3% in the general population (34,
44). We have also noted a high prevalence of scoliosis (5–10%)
in PCD, as noted by others (52). Thus, PCD should be considered




The diagnosis is delayed inEuropean childrenwith PCD (median
age of diagnosis, z5.5 yr) (53). We note similar findings in our
North American rare disease consortium (median age of diagno-
sis,z5 yr for children and 22 yr for adults); therefore, physicians
should increase their index of suspicion for PCD in patients with
pertinent phenotypes. As most institutions do not have adequate
resources for a rigorous diagnostic evaluation, referral to special-
ized centers is strongly recommended. Patients appropriate for
referral include those with situs inversus with any respiratory
disease, unexplained neonatal respiratory distress, early onset
and persistent nasal congestion and daily cough, bronchiectasis
without a defined etiology, and/or a family history of PCD in
a sibling. For adults, all males with dyskinetic (or immotile) sper-
matozoa should be considered for PCD if they have respiratory
symptoms. Females who are infertile or subfertile without an
obvious cause, particularly if they have features of PCD, should
be evaluated. Several medical disorders and phenotypes coexist
with PCD, including complex congenital heart disease, laterality
defects, retinitis pigmentosa, hydrocephalus, pectus excavatum,
and scoliosis (1–4, 44, 52, 54).Weare trying todefine theprevalence
of overlap of PCD with primary/sensory ciliopathies, such as
Bardet-Biedl or Alstrom syndromes, but a family history of an as-
sociated “ciliopathy” should raise the index of suspicion for PCD. It
is noteworthy that there is an increased incidence (z1 in 2,000) of
PCD in a highly consanguineous Asian population (55).
Clinical Phenotype
A key factor in evaluation of patients with chronic respiratory
disease is identification of phenotypic features that characterize
PCD as compared with other diseases (9). This is particularly
true for infants or children who have not developed bronchiec-
tasis (34–36) (Table 1). A history of neonatal respiratory dis-
tress, despite term birth, is a prevalent feature (over 80%), and
a useful marker of PCD (18–20). Situs abnormalities are a rela-
tively specific marker for distinguishing PCD from other chil-
dren with chronic respiratory symptoms. The early onset and
persistence of respiratory symptoms may help distinguish PCD
from other disorders with more episodic respiratory symptoms
(18, 19). Typically, the chronic nasal congestion/drainage and
chronic wet cough in PCD occur on a daily basis throughout the
year, and usually start in infancy. Most children with PCD can
expectorate sputum with surprisingly little effort. Chronic otitis
media often appears in the first months of life, and is charac-
terized by the persistence of middle ear fluid, despite antibiotics
or placement of tympanostomy tubes (18, 19). Chest CT scans
are rarely performed in young children with recurrent respira-
tory symptoms; however, if bronchiectasis is defined in a young
child, PCD is highly likely, particularly if CF has been ruled out
(21, 34–36). Symptoms that comprise a strong clinical pheno-
type in PCD in young children include (1) neonatal respiratory
distress, and/or (2) chronic, persistent lower respiratory symp-
toms (early onset and persistent wet cough), and/or (3) chronic,
persistent upper respiratory symptoms (nasal congestion and
otitis media), and/or (4) a laterality defect (situs inversus or
ambiguus). Indeed, the presence of any two of these four hall-
mark clinical features provides a strong clinical phenotype for
PCD, assuming that CF has been excluded (19).
Ciliary Ultrastructure in PCD
Identification of ultrastructural defects on electron microscopy
(EM) has been the traditional test used to confirm a diagnosis
of PCD, but this approach can no longer be the sole “gold
standard” for diagnosis. This approach cannot be used to diag-
nose the growing number of patients with PCD (at least 30%)
with normal ultrastructure. For those patients with PCD with
ultrastructural defects, the majority of defects (z55%) involve
the absence or shortening of ODAs (40%), or an ODA defect
in conjunction with an IDA defect (15%) (Figure 2). Isolated
IDA defects comprise only a small fraction (,5%) of confirmed
PCD, and false-positive diagnoses commonly occur with these
IDA defects (9, 56). Before an isolated IDA defect can be used
to validate a diagnosis of PCD, a ciliary biopsy for EM must be
repeated when the nasal epithelium is healthy. The vast major-
ity of verified IDA defects have associated central apparatus
abnormalities that may occur in only a small subset (5–20%)
of cilia (Figure 2). These central apparatus defects include mi-
crotubular disorganization and transposition of outer doublets
into the central area of the cilia cross-sections, and frequently
reflect mutations in CCDC39 or CCDC40 (57, 58). Early reports
suggested that ciliary “disorientation” (misalignment of the cen-
tral pair) was a cause of PCD (59, 60), but more recent studies
have demonstrated that misalignment of the central pair is a sec-
ondary change, and should not be used as a diagnostic ultra-
structural criterion (61). A few patients are reported to have
absence of cilia on multiple biopsies, suggesting ciliary aplasia,
but this finding is difficult to prove, as no genetic etiology has
been identified for these patients.
Transmission EM testing of cilia has additional limitations,
due to challenges in obtaining adequate specimens, technical fac-
tors in processing specimens, and interpretation of images (9,
62). This perspective was highlighted by the experience in our
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rare disease consortium, where as many as 15–20% of the
patients referred with a “confirmed” diagnosis of PCD (based
on ciliary ultrastructure) had a false-positive diagnosis of PCD.
For successful ciliary EM testing, the specimen can be from
either the nose or bronchi, but cilia should be obtained when
there is no significant inflammation, because the normal 9 1 2
microtubular pattern can be altered during respiratory infec-
tions, or if cells are poorly fixed. Processing of ciliary biopsy
specimens is highly specialized, but not well standardized. Many
EM cross-sections (at least 30 sections containing .60 high-
quality cilia images is desirable) should be examined by expe-
rienced readers, and a quantitative approach to interpretation is
critical, because ciliary EMs from normal subjects may have
only seven or eight visible ODAs, and only three visible IDAs,
per cilium (9, 63). EM analysis is more feasible in biopsies from
adults versus children, likely due to the technical challenges of
obtaining adequate “scrape” biopsies from narrow airways (10,
62). Acquired (secondary) ciliary defects result from airway
damage from recurrent infections, and can sometimes be diffi-
cult to differentiate from PCD.
It is critical to recognize that at least 30% of patients with
a strong PCD clinical phenotype and low nNO have normal
ciliary EMs. Many of these have been confirmed by genetic test-
ing; for example, a recent study demonstrated that 22% of 61
such patients have PCD-causing mutations in DNAH11 (64).
Thus, normal ciliary ultrastructure cannot rule out PCD.
Ciliary Beat Frequency and Motility
Assessment of ciliary motility from fresh biopsies of airway (usu-
ally nasal) epithelium has been a traditional approach to confirm
a diagnosis of PCD; however, due to substantial limitations, this
cannot be the sole diagnostic approach. Although a useful tech-
nique in patients with immotility or gross dysmotility of all cilia,
accurate recognition of more subtle motility defects requires ex-
perienced investigators (9, 27, 65). It is recognized that standard
light microscopic analysis is not sufficient (66). Even with high-
speed video microscopy, there are recognized limitations due to:
(1) effects of infection and inflammation on cilia; (2) disruption of
epithelium during sample collection; (3) lack of quantitative data
to allow rigorous interpretation of waveform analyses; and (4)
overlap of ciliary beat frequency between PCD and disease-
control and normal subjects (67, 68). Approaches to improve
accuracy include ciliated air–liquid cultures to reduce the effects
of infection/inflammation, and cooling the specimen to slow cilia
beat frequency for waveform analysis; however, these modifica-
tions do not eliminate all of the limitations (69–71). Another
problem that has been recognized through genetic testing is that
many forms of PCD have no, or only subtle, abnormalities of
ciliary ultrastructure and/or beat frequency and waveform.
Therefore, these biological assays of ciliary structure/function
are not sensitive to detecting the growing range of ciliary pheno-
types in PCD.
nNO
nNO levels in patients with PCD are low (10–20% of normal
values, which range from 125 to 867 nl/min; mean, 287 nl/min),
suggesting that nNOmaybe auseful test for PCD(3, 9, 14–16, 37).
nNO can be measured by aspirating nasal air through a catheter
placed at the opening of one nostril and directed to an NO ana-
lyzer (72). Because exhaled air from the lower airways has amuch
lower concentration of NO than nasal gases, maneuvers must be
instituted to close the soft palate and thereby limit contamination
of nasal air by air from the lower airways (72). These techniques
have beenused reproducibly in adults and children over 5 years of
age, but often are not possible in younger children. As an alter-
native, some centers have measured nNO during tidal breathing
in infants and young children (73). In healthy subjects, nNO val-
ues during tidal breathing are approximately 40% lower than
values obtained at plateau during palate closure. Low nNO levels
have also been reported in some patients with CF (9, 37); there-
fore, sweat testing orCFTR genetic studies should be done to rule
out CF, if nNO is low. Low nNO values have also been reported
during acute viral infections, acute sinusitis, and panbronchiolitis;
therefore, measurements should be taken when there are no
acute changes in respiratory status, and repeated on a separate
day for confirmation (3, 9). To date, nNO has been used in a lim-
ited number of specialized centers as a reliable test for PCD, and
is currently being extended to the growing network of PCD
Figure 2. Ciliary ultrastructure by electron micrographs (EMs) from (A)
normal subject and (B–F) patients with primary ciliary dyskinesia (PCD).
(A) The 9 1 2 axonemal structure is shown, with thick red arrows show-
ing the outer dynein arm (ODA) and thin green arrow showing the inner
dynein arm (IDA). (B) ODA defect denoted by thick red arrows
(CCDC114 mutations). (C and D) Patient with PCD with CCDC40 muta-
tions: (C) IDA defect denoted by thin green arrows, and (D) microtubular
disorganization with one outer doublet translocating (disruption of 91
2 axonemal structure) into the central region in approximately 10% of
cilia. (E) ODA 1 IDA defects noted by thick red arrow and thin green
arrow. (F) Central apparatus defect; translocation of outer doublet into
central region and loss of one of the central pair (seen in z5% of cilia
with radial spokehead gene mutations).
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centers, recognizing that there must be meticulous attention to
details of the standard operating procedures.However, with stan-
dardization, and definition of appropriate cut-off values, nNO
measurement could be used more widely as a diagnostic test for
PCD.
Other Methods of Diagnosis
Fluorescence-labeled antibodies have been successfully used to
demonstrate absence of cilia axonemal and cytoplasmic preas-
sembly of proteins, but only a few laboratories have tested this
approach (2, 74–77). Measurement of mucociliary clearance in
the lung has been used by some investigators, but has been
reported to be inadequate, because it cannot be performed in
young children and is confounded by involuntary cough and
bronchiectasis from other etiologies (78). The nasal saccharine
clearance test has no role as a current diagnostic method, due to
multiple limitations in performance and interpretation of the
test.
GENETIC TESTING
Disease-Causing Genetic Mutations in PCD
PCD is aMendelian recessive and genetically heterogeneous dis-
order. Between 1999 and 2010, PCD-causing mutations were de-
scribed in11genesbasedonhomozygositymappingandcandidate
gene testing (see review articles, References 2, 16, 17, and Table
2). Since early 2011, there has been an explosion of discovery,
facilitated by exome sequencing, whereby PCD-causing muta-
tions in 10 additional genes have been published (57, 58, 75–77,
79–85) (see Table 2). The vast majority (85%) of the mutations
are loss-of-function variants (nonsense, frameshift, or defective
splice mutants), and approximately 15% are conservative mis-
sense mutations. There are founder (or recurring) mutations in
some genes that are common to many patients, but most of the
mutations occur in only one family/patient. There are multiple
other recently discovered novel genes with mutations in patients
with PCD (henceforth, referred to as “PCD genes”) that are in
different stages of validation and publication. Based on identifi-
cation of genetic mutations in over 200 patients with PCD in our
rare disease consortium, it is estimated that approximately 65%
of patients with PCD can be identified as having biallelic muta-
tions in one of these 21 published PCD genes. The upcoming
publications of recently discovered novel genes and additional
discoveries from exome sequencing make it likely that over
80% of patients with PCD can be identified by genetic testing
within the next few years using high-throughput genetic technol-
ogies. If true, this will revolutionize the diagnostic approach in
PCD, and lead to early identification and initiation of clinical
monitoring and treatment.
The roles of PCD genes in normal ciliary biogenesis and func-
tion, andtheeffectofmutationsoncilia structureandfunction, are
detailed in many publications (2, 16, 17, 57, 58, 75–77, 79–83), but
several key observations are emerging. First, there is very strong
correlation between mutations in specific genes and effect on
ciliary ultrastructure. Most of the genes code for proteins in the
ciliary axonemes in the ODA, or IDA, or radial spoke, but six of
these genes are expressed in the cytoplasm, and play a role in
preassembly of the cilia. Mutations in these six cytoplasmic genes
(see Table 2) lead to loss of both ODA and IDA, and are associ-
ated with ciliary immotility or severe dysmotility. Second, bial-
lelic loss-of-function mutations lead to low nNO (,77 nl/min),
regardless of the PCD-causing gene. Third, genetic studies con-
firm the relationship between ultrastructural dynein arm defects
and situs abnormalities (i.e., mutations in genes that code for
dynein arm components are associated with laterality defects,
but mutations in genes that code for central apparatus compo-
nents are not). Fourth, genetic discovery provides opportunity to
examine ciliary EMs from multiple patients with mutations in the
samePCD-causing gene, and allows recognition of subtle changes,
such as IDA defects associated with microtubular disorganization
involving only 10% of cilia (e.g., mutations in CCDC39 and
CCDC40). Finally, genetic mutations in patients with PCD with
normal ciliary ultrastructure offer irrefutable confirmation that
PCDcanoccur in the absence of ciliaryEMdefects. Furthermore,
the ciliary beat frequency in patients with mutations in these
genes (e.g., DNAH11, RSPH4A, RSPH9) with normal EMs can
benormal (or higher thannormal), and thewaveforms can appear
normal, or have only subtle defects.We anticipate that additional
novelPCD-causing geneswill emerge fromongoing research, and
that some of these patients may have a different (milder) pheno-
type than seen in classic PCD with ultrastructural defects.
MANAGEMENT OF LUNG DISEASE
Overview
Pulmonary disease in PCD reflects the loss of the key innate lung
defense mechanism, mucociliary clearance, and symptoms begin
early in life. There are no validated PCD-specific therapies; thus,
therapies for PCDare extrapolated from another diseasewith de-
fectivemucociliary clearance, CF, and frompatients with non-CF
bronchiectasis, particularly as relates to antibiotic therapy andmac-
rolides as antiinflammatory agents (86–90).We concur with recom-
mendations of the European Respiratory Society for management
of lung disease in PCD, including routine airway clearance, the use
of antibiotics to control infection, and theeliminationof exposure to
inflammatory triggers, including passive smoke (3).
Monitoring Pulmonary Status
Clinic visits at least twice per year are suggested for spirometric
monitoring and respiratory culture surveillance, including NTM.
Patients with PCD can readily expectorate sputum for this pur-
pose. Periodic imaging studies are also indicated to monitor the
extent of disease. Preventive measures include infection control
training and routine immunizations, as well as pneumococcal and
influenza vaccine.
Antibiotic Therapy for Lung Disease
Studies inCFandnon-CFbronchiectasis (including somepatients
with PCD) demonstrate that systemic antibiotics are effective at
treating “exacerbations” (worsening respiratory symptoms) of
lung disease (86, 87). Antibiotics should be chosen based on
respiratory culture data. Surprisingly, early (small) studies of
chronic inhaled antibiotics in non-CF bronchiectasis did not show
benefit in spirometric parameters, although some studies showed
a reduction of neutrophil elastase activity in sputum (91). A
recent 12-month-long, controlled study of inhaled gentamicin
demonstrated striking benefit to reduce frequency of exacerba-
tions, and reduce the burden of bacteria and markers of pulmo-
nary and systemic inflammation (92). For patients with PCDwho
develop airway infection with P. aeruginosa, it is noteworthy that
one study in patients with non-CF bronchiectasis demonstrated
high rates of eradication ofP. aeruginosa (90).Agoal for thePCD
community is to develop the requisite elements (patients, sites,
outcome measures) to perform prospective studies of pertinent
therapies in PCD.
Osmotic Agents and Dornase a
Stimulation of Cl2 (and liquid) secretion by an inhaled agent
(P2Y2 receptor agonist) improved cough clearance of radiolabeled
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particles in a small study of adults with PCD (93). Recently, neb-
ulized 7% hypertonic saline over 3 months improved lung function
and quality of life, and reduced antibiotic use in non-CF bronchi-
ectasis (94). The presumption is that stimulation of cough and
increased hydration of airway secretions with hypertonic saline
or other osmotic agents can benefit tracheobronchial clearance
in non-CF bronchiectasis. By analogy, hydrating airway secre-
tions may facilitate cough clearance in PCD, even though muco-
ciliary clearance remains defective. In contrast to beneficial
effects in CF, dornase alfa has not been shown to improve pulmo-
nary status in non-CF bronchiectasis; indeed, adults with non-
CF bronchiectasis taking dornase alfa for 24 weeks experienced
more pulmonary exacerbations and a more significant decline in
FEV1 compared with the placebo group (95).
Antiinflammatory Therapy
Oral macrolides are clearly effective in reducing exacerbations in
CF through antiinflammatory mechanisms (86). Similar data are
emerging in relatively small studies in non-CF bronchiectasis, as
relates to reduction in exacerbations (88, 89). In contrast to CF,
most of the patients with non-CF bronchiectasis have bacterial
infections other than P. aeruginosa, so the mechanism of
macrolide effects in non-CF bronchiectasis could relate to












% of Individual with
Biallelic Mutations MIM No. References
DNAH5 5p15.2 DHC ɣ ODA defect Yes 15–21% of all PCD, 27–38%
of PCD with ODA defects
608644 2, 16
DNAI1 9p21-p13 IC78 ODA defect Yes 2–9% of all PCD, 4–13% of
PCD with ODA defects
244400 2, 16
DNAI2 17q25 IC69 ODA defect Yes 2% of all PCD, 4% of PCD
with ODA defects
612444 16
DNAL1 14q24.3 LC1 ODA defect Yes na 614017 16, 81
CCDC114 19q13.32 DC2 ODA defect Yes 6% of PCD with ODA defects 615038 83, 84
TXNDC3
(NME8)
7p14-p13 LC5 Partial ODA defect
(66% cilia defective)
Yes na 610852 16
DNAAF1
(LRRC50)










19q13.42 PF22 ODA 1 IDA defect Yes na 606763 75
CCDC103 17q21.31 PR46b ODA 1 IDA defect Yes na 614679 77




ODA 1 IDA defect Yes na 614864 79
LRRC6 8q24 MOT47 ODA 1 IDA defect Yes 11% of PCD with ODA 1
IDA defects
614930 80
CCDC39 3q26.33 FAP59 IDA defect 1 axonemal
disorganization




CCDC40 17q25.3 FAP172 IDA defect 1 axonemal
disorganization




RSPH4A 6q22.1 RSP4, RSP6 Mostly normal, CA
defects in small
proportion of cilia
No na 612649 16
RSPH9 6p21.1 RSP9 Mostly normal, CA
defects in small
proportion of cilia
No na 612648 16
HYDIN 16q22.2 hydin Normal, very occasionally
CA defects
No na 610812 76














2p23.3 DRC1 Nexin (N-DRC) link
missing; axonemal
disorganization in
small proportion of cilia
No na 312610 85
Definition of abbreviations: CA ¼ central apparatus; IDA ¼ inner dynein arm; MIM ¼ Mendelian inheritance in man; na ¼ not available; N-DRC ¼ nexin–dynein
regulatory complex; ODA ¼ outer dynein arm; PCD ¼ primary ciliary dyskinesia.
MIM number is the online MIM (www.ncbi.nlm.nih.gov/omim), which is a continuously updated catalog of human genes, genetic disorders, and traits, with particular
focus on the molecular relationship between genetic variation and phenotype expression.
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antibiotic effect, as well as an antiinflammatory effect. The de-
velopment of microbial resistance with chronic macrolides is of
concern. Current practice guidelines suggest that patients should
not receive chronic oral macrolides unless they have been tested
and shown to not harbor NTM (86, 88, 89). The widespread use
of inhaled or systemic corticosteroids in CF and non-CF bronchi-
ectasis has been debated due to the risk–benefit ratio.
Lung Resection and Lung Transplantation
PCD affects all regions of the lung. Resection of lung in PCD is
occasionally useful, but should be undertaken only after careful
consideration and consultation with PCD experts. Patient selec-
tion should focus on thosewith severe localizedbronchiectasiswith
recurrent febrile relapses or severe hemoptysis, despite aggressive
medical management (96). Patients with PCDwith end-stage lung
disease are candidates for lung transplantation, anda small number




Management of otitis media with effusion is controversial, even
though it affects almost all children with PCD, and has implica-
tions for conductive hearing loss, delayed speech and language
development, and cholesteatoma formation (18, 97). Advocates
of tympanostomy (ventilation) tubes suggest that hearing may
be improved (long term) in some patients, and otorrhea can be
controlled (97). In contrast, the European Respiratory Society
Consensus Statement recommends against placement of tubes
for chronic otitis media in patients with PCD, because resultant
otorrhea is a problem, and spontaneous resolution of chronic
otitis media may occur in the teenage years (3, 98). Episodes of
otitis media should be treated by standard approaches, but data
are not available to address the question of surgical intervention.
Although middle-ear symptoms typically decrease over time, it
should be recognized that chronic otitis media may persist into
adulthood, and conductive hearing loss (glue ear) occurs in some
patients. Therefore, audiology assessments, hearing aids, and
communication assistance should be encouraged.
Chronic Sinusitis
Sinus disease is a major problem for many patients with PCD.
Initial management includes nasal steroids, nasal lavage, and in-
termittent courses of systemic antibiotics. Polyps may require
surgery. Functional endoscopic sinus surgery is helpful in many
patients that are refractory to medical therapy, particularly if
there is aggressive postsurgical treatment to maintain adequate
drainage (99, 100).
FUTURE DIRECTIONS
PCD Diagnostic and Treatment Centers
Treatment of patients with PCD is not standardized, and many
patients with PCD receive suboptimal management, including
many who do not have regular surveillance of respiratory micro-
biology, andmany have not received regular treatment with anti-
biotics targeted to pathogens. A multidisciplinary approach to
management of chronic disease is well recognized to benefit
long-term outcomes, particularly for rare diseases. Because CF
shares many features of PCD lung disease, and has established
a successful clinical network, the PCD Foundation is developing
a network of PCD clinical centers, which frequently involve CF
center clinicians. In addition to the eight sites already active in
our rare disease consortium, the PCD Foundation has recently
selected additional sites to be recognized for the care of patients
withPCD,whichshouldalleviatesomeoftheinconsistencyincare.
This approachwill also facilitate the identificationof patientswith
PCD for participation in prospective clinical trials, and create the
opportunity to partner with European PCD centers for trials.
Note added in proofs: Since the preparation and acceptance
of this manuscript, the following have been identified as PCD
disease-causing mutations and published in the literature (MIM#
given in parentheses): ARMC4 (615408), DYX1C1 (608706),
ZMYND10 (607070), CCDC65 (611088), RSPH1 (609314), and
SPAG1 (603395).
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